These are the sources and citations used to research Health. This bibliography was generated on Cite This For Me on
In-text: (Attwood, Rask-Andersen and Schiöth, 2018)
Your Bibliography: Attwood, M., Rask-Andersen, M. and Schiöth, H., 2018. Orphan Drugs and Their Impact on Pharmaceutical Development. Trends in Pharmacological Sciences, 39(6), pp.525-535.
In-text: (Azoulay, 2004)
Your Bibliography: Azoulay, P., 2004. Capturing Knowledge within and across Firm Boundaries: Evidence from Clinical Development. American Economic Review, 94(5), pp.1591-1612.
In-text: (Banerjee and Siebert, 2017)
Your Bibliography: Banerjee, T. and Siebert, R., 2017. Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry. Research Policy, 46(7), pp.1255-1271.
In-text: (Berndt, 2002)
Your Bibliography: Berndt, E., 2002. Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price. Journal of Economic Perspectives, 16(4), pp.45-66.
In-text: (Danzon and Pauly, 2002)
Your Bibliography: Danzon, P. and Pauly, M., 2002. Health Insurance and the Growth in Pharmaceutical Expenditures. The Journal of Law and Economics, 45(S2), pp.587-613.
In-text: (DiMasi, Grabowski and Hansen, 2016)
Your Bibliography: DiMasi, J., Grabowski, H. and Hansen, R., 2016. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, pp.20-33.
In-text: (Dunn, 2012)
Your Bibliography: Dunn, A., 2012. Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-Cholesterol Drugs. American Economic Journal: Applied Economics, 4(3), pp.167-189.
In-text: (Dunne, Shannon, Dunne and Cullen, 2013)
Your Bibliography: Dunne, S., Shannon, B., Dunne, C. and Cullen, W., 2013. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacology and Toxicology, 14(1).
In-text: (Ellison, Cockburn, Griliches and Hausman, 1997)
Your Bibliography: Ellison, S., Cockburn, I., Griliches, Z. and Hausman, J., 1997. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. The RAND Journal of Economics, 28(3), p.426.
In-text: (Orphan designation: Overview - European Medicines Agency, 2021)
Your Bibliography: European Medicines Agency. 2021. Orphan designation: Overview - European Medicines Agency. [online] Available at: <https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview> [Accessed 8 January 2021].
In-text: (Frick and Chernew, 2009)
Your Bibliography: Frick, K. and Chernew, M., 2009. Beneficial Moral Hazard and the Theory of the Second Best. INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 46(2), pp.229-240.
In-text: (Frost & Sullivan, 2019)
Your Bibliography: Frost & Sullivan, 2019. Global pharmaceutical market in-house vs outsourcing services share 2014-2023 Published by Matej Mikulic, Jan 15, 2020 Throughout the given period, the percentage of in-house spending is expected to decrease from 66.3 percent in 2014 to almost 51 percent in 2023. This statistic shows the percent distribution of in-house and outsourcing services expenditure in the global pharmaceutical market from 2014 to 2023. Distribution of in-house and outsourcing services expenditure in the global pharmaceutical market from 2014 to 2023. [online] https://www.statista.com/. Available at: <https://www-statista-com.eaccess.ub.tum.de/statistics/1085611/global-pharma-market-internal-vs-outsourced-services-expenditure-share/> [Accessed 4 January 2021].
In-text: (Grabowski, Brain, Taub and Guha, 2017)
Your Bibliography: Grabowski, H., Brain, C., Taub, A. and Guha, R., 2017. Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes. American Journal of Health Economics, 3(1), pp.33-59.
In-text: (Hellerstein, 1998)
Your Bibliography: Hellerstein, J., 1998. The Importance of the Physician in the Generic versus Trade-Name Prescription Decision. The RAND Journal of Economics, 29(1), p.108.
In-text: (Iizuka, 2008)
Your Bibliography: Iizuka, T., 2008. Experts' agency problems: evidence from the prescription drug market in Japan. The RAND Journal of Economics, 38(3), pp.844-862.
In-text: (Jayasundara et al., 2019)
Your Bibliography: Jayasundara, K., Hollis, A., Krahn, M., Mamdani, M., Hoch, J. and Grootendorst, P., 2019. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases, 14(1).
In-text: (Kaier, 2012)
Your Bibliography: Kaier, K., 2012. The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials. Health Economics, Policy and Law, 8(1), pp.7-20.
In-text: (Kesselheim, 2010)
Your Bibliography: Kesselheim, A., 2010. Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation. New England Journal of Medicine, 363(19), pp.1855-1862.
In-text: (Lakdawalla, 2018)
Your Bibliography: Lakdawalla, D., 2018. Economics of the Pharmaceutical Industry. Journal of Economic Literature, 56(2), pp.397-449.
In-text: (Leerapan, 2014)
Your Bibliography: Leerapan, B., 2014. International Health Systems: The Western.
In-text: (Limbrock, 2011)
Your Bibliography: Limbrock, F., 2011. Pecuniary and Non-Pecuniary Incentives in Prescription Pharmaceuticals: The Case of Statins. The B.E. Journal of Economic Analysis & Policy, 11(2).
In-text: (Liu and Chollet, 2006)
Your Bibliography: Liu, S. and Chollet, D., 2006. Price and Income Elasticity of the Demand for Health Insurance and Health Care Services: A Critical Review of the Literature. Mathematica Policy Research Reports, [online] Available at: <https://EconPapers.repec.org/RePEc:mpr:mprres:dbf03ba11863430593b0b825fb48acc2.> [Accessed 10 January 2021].
In-text: (Luzzatto et al., 2018)
Your Bibliography: Luzzatto, L., Hyry, H., Schieppati, A., Costa, E., Simoens, S., Schaefer, F., Roos, J., Merlini, G., Kääriäinen, H., Garattini, S., Hollak, C., Remuzzi, G., Barbui, T., Benigni, A., Costa, E., Daina, E., Garattini, S., Gramaglia, D., Hollak, C., Hyry, H., Kaarinen, H., Licht, C., Luzzatto, L., Merlini, G., Notaro, R., Remuzzi, G., Schaefer, F., Schieppati, A. and Simoens, S., 2018. Outrageous prices of orphan drugs: a call for collaboration. The Lancet, 392(10149), pp.791-794.
In-text: (Morgan, Roberts and Edwards, 2018)
Your Bibliography: Morgan, M., Roberts, O. and Edwards, A., 2018. Ideation and implementation of an open science drug discovery business model – M4K Pharma. Wellcome Open Research, 3, p.154.
In-text: (partners4access, 2018)
Your Bibliography: partners4access, 2018. Dear orphan drug industry, are you prepared?. [image] Available at: <https://partners4access.com/wp-content/uploads/2018/02/infographic.png> [Accessed 8 January 2021].
In-text: (Rao, 2015)
Your Bibliography: Rao, A., 2015. Entry and Investment Decisions in the Pharmaceutical Industry. SSRN Electronic Journal,.
In-text: (Ridley, 2013)
Your Bibliography: Ridley, D., 2013. PAYMENTS, PROMOTION, AND THE PURPLE PILL. Health Economics, 24(1), pp.86-103.
In-text: (Ringel, Hosek, Vollaard and Mahnovski, 2002)
Your Bibliography: Ringel, J., Hosek, S., Vollaard, B. and Mahnovski, S., 2002. The Elasticity of Demand for Health Care: A Review of the Literature and Its Application to the Military Health System. Santa Monica, CA: RAND Corporation.
In-text: (Rudy and Black, 2015)
Your Bibliography: Rudy, B. and Black, S., 2015. Attack or Defend? The Role of Institutional Context on Patent Litigation Strategies. Journal of Management, 44(3), pp.1226-1249.
In-text: (SB et al., 2014)
Your Bibliography: SB, C., Puranik, S., Sagar, P., Sreenivasa, S. and Rao, M., 2014. Patent process. [image] Available at: <https://www.rroij.com/open-access/patents--an-important-tool-for-pharmaceutical-industry-.php?aid=34351> [Accessed 8 January 2021].
In-text: (Scherer, 2000)
Your Bibliography: Scherer, F., 2000. Chapter 25 The pharmaceutical industry. Handbook of Health Economics, 1, pp.1297-1336.
In-text: (Scott Morton and Kyle, 2011)
Your Bibliography: Scott Morton, F. and Kyle, M., 2011. Chapter Twelve - Markets for Pharmaceutical Products. Handbook of Health Economics, 2, pp.763-823.
In-text: (Thiers, Sinskey and Berndt, 2008)
Your Bibliography: Thiers, F., Sinskey, A. and Berndt, E., 2008. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery, 7(1), pp.13-14.
In-text: (How U.S. Health Insurance Works | Vaden Health Services, 2021)
Your Bibliography: Vaden.stanford.edu. 2021. How U.S. Health Insurance Works | Vaden Health Services. [online] Available at: <https://vaden.stanford.edu/insurance/health-insurance-overview/how-us-health-insurance-works> [Accessed 10 January 2021].
10,587 students joined last month!